MX2019013750A - Un metodo para producir ranibizumab humanizado recombinante replegado. - Google Patents

Un metodo para producir ranibizumab humanizado recombinante replegado.

Info

Publication number
MX2019013750A
MX2019013750A MX2019013750A MX2019013750A MX2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A
Authority
MX
Mexico
Prior art keywords
recombinant humanized
ranibizumab
refolded recombinant
producing
producing refolded
Prior art date
Application number
MX2019013750A
Other languages
English (en)
Inventor
Rahul Sharad Bhambure
Kayanat Mahammadtaki Gani
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of MX2019013750A publication Critical patent/MX2019013750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

La presente invención se refiere a un novedoso proceso de clonación, expresión y repliegue para preparar fragmentos de anticuerpo; mas particularmente, la presente invención se refiere a una plataforma de clonación, expresión y repliegue para preparar 5 Ranibizumab humanizado recombinante (rHu).
MX2019013750A 2017-05-19 2018-05-18 Un metodo para producir ranibizumab humanizado recombinante replegado. MX2019013750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711017654 2017-05-19
PCT/IN2018/050315 WO2018211529A1 (en) 2017-05-19 2018-05-18 A method for producing refolded recombinant humanized ranibizumab

Publications (1)

Publication Number Publication Date
MX2019013750A true MX2019013750A (es) 2020-07-20

Family

ID=62599663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013750A MX2019013750A (es) 2017-05-19 2018-05-18 Un metodo para producir ranibizumab humanizado recombinante replegado.

Country Status (9)

Country Link
US (2) US11524996B2 (es)
EP (1) EP3624847A1 (es)
JP (1) JP7282689B2 (es)
KR (1) KR102607655B1 (es)
CN (1) CN110636859A (es)
BR (1) BR112019023795A2 (es)
CA (1) CA3063320A1 (es)
MX (1) MX2019013750A (es)
WO (1) WO2018211529A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220177562A1 (en) * 2019-04-02 2022-06-09 Council Of Scientific & Industrial Research Cloning and expression of in vivo refolded antibody fragment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
JP2003102494A (ja) * 2001-07-26 2003-04-08 Sangaku Renkei Kiko Kyushu:Kk 蛋白質のリフォールディング方法及び連続リフォールディング方法並びに連続リフォールディング装置
JP2008512085A (ja) * 2004-06-03 2008-04-24 ネオス テクノロジーズ インコーポレイティッド 切断型ＧａｌＮＡｃＴ２ポリペプチドおよび核酸
JP5566104B2 (ja) 2006-07-14 2014-08-06 ジェネンテック， インコーポレイテッド 組み換えタンパク質の再折り畳み
WO2008151319A2 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
KR101671886B1 (ko) 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2013076657A1 (en) 2011-11-22 2013-05-30 Lupin Limited Map fusion protein
SG10201700169PA (en) * 2011-12-22 2017-02-27 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
CN102757496B (zh) 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
US9914770B2 (en) 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
RU2732148C2 (ru) * 2014-07-09 2020-09-11 Люпин Лимитед Двухцистронная бактериальная система экспрессии
AU2016307976A1 (en) * 2015-08-17 2018-03-08 Lupin Limited An improved refolding process for antibody's fragments

Also Published As

Publication number Publication date
BR112019023795A2 (pt) 2020-07-28
US11578122B2 (en) 2023-02-14
US11524996B2 (en) 2022-12-13
JP2020520642A (ja) 2020-07-16
JP7282689B2 (ja) 2023-05-29
US20200140535A1 (en) 2020-05-07
EP3624847A1 (en) 2020-03-25
CA3063320A1 (en) 2018-11-22
KR102607655B1 (ko) 2023-11-28
KR20200008147A (ko) 2020-01-23
US20200165332A1 (en) 2020-05-28
CN110636859A (zh) 2019-12-31
WO2018211529A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
EP3708660A3 (en) Polypeptides
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
PE20180481A1 (es) Anticuerpos de union a tau
MY196181A (en) Aerosol-Generating Material Rod Segment
NZ758093A (en) Monoclonal antibody to pd-l1
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2019000415A (es) Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
TW201613967A (en) Interferon alpha and omega antibody antagonists
MX2021004454A (es) Anticuerpos anti-sinucleina.
HK1254752A1 (zh) 用於抗體碎片的改進的複性方法
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
MX2019013750A (es) Un metodo para producir ranibizumab humanizado recombinante replegado.
NZ724772A (en) Antibodies against hpa-1a
MX2019007978A (es) Mezcla para la fabricacion de un producto ceramico refractario no moldeado, procedimiento para la fabricacion de un producto ceramico refractario no moldeado asi como un producto ceramico refractario no moldeado fabricado por ello.
MX2018013562A (es) Metodo de produccion de una proteina recombinante.
SG11202107697UA (en) Method for producing recombinant protein
MX2020013380A (es) Producto refractario, una mezcla para la fabricacion del producto, un procedimiento para la fabricacion del producto asi como un uso del producto.